# Alkermes (ALKS) — News

ALKS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/alks/news

## Recent headlines

- [PLC Resources Ltd - Geo-spectral survey commences at Abbotts Gold project, WA](https://www.ainvest.com/news/plc-resources-geo-spectral-survey-commences-abbotts-gold-project-wa-2610) — AInvest Wire, Oct 13, 2026
  PLC Resources Ltd (ASX: PLC) has announced the commencement of a geo-spectral survey at its Abbotts Gold project in Western Australia. The survey is part of the company’s ongoing exploration efforts to identify potential gold-bearing structures within the project area. Geo-spectral surveys utilise…
- [Bio-pharmaceutical stocks fell in regular trading, with Eton Pharmaceuticals down 3.3%, Livent down 5.0% and BioTelemetry down 6.2%.](https://www.ainvest.com/news/bio-pharmaceutical-stocks-fell-regular-trading-eton-pharmaceuticals-3-3-livent-5-0-biotelemetry-6-2-2609) — AInvest Wire, Sep 30, 2026
  On September 30, 2026, bio-pharmaceutical stocks experienced declines in regular trading, with several companies posting notable losses. Eton Pharmaceuticals fell 3.3%, Livent dropped 5.0%, and BioTelemetry declined by 6.2%. The sector has faced ongoing scrutiny due to stretched valuations and…
- [Alkermes PLC: Jefferies raises target price to $83 from $78](https://www.ainvest.com/news/alkermes-plc-jefferies-raises-target-price-83-78-2609) — AInvest Wire, Sep 22, 2026
- [Alkermes PLC: Baird raises target price to $61 from $58](https://www.ainvest.com/news/alkermes-plc-baird-raises-target-price-61-58-2609) — AInvest Wire, Sep 21, 2026
  Baird Financial Group Inc. has raised its price target for Alkermes PLC (NASDAQ: ALKS) to $61 from $58, while maintaining an "Outperform" rating on the stock. This adjustment follows recent developments in Alkermes’s pipeline, including positive Phase I data for its ADHD candidate, ALKS 7290, and…
- [Alkermes' ALKS 7290 meets ADHD endpoints in phase 1B](https://www.ainvest.com/news/alkermes-alks-7290-meets-adhd-endpoints-phase-1b-2609) — AInvest Wire, Sep 21, 2026
  Alkermes is currently evaluating ALKS 7290, an investigational orexin 2 receptor agonist, in a phase 2 study for ADHD . While the source materials do not provide specific results from a phase 1B trial, the progression of ALKS 7290 to phase 2 indicates that early-stage development has met necessary…

## Similar Stocks

- [MEDP](https://www.lighthorse.io/tickers/medp) — Medpace Holdings, Inc. - Common Stock
- [AMN](https://www.lighthorse.io/tickers/amn) — AMN Healthcare Services Inc
- [OMCL](https://www.lighthorse.io/tickers/omcl) — Omnicell, Inc. - Common Stock
- [ABEO](https://www.lighthorse.io/tickers/abeo) — Abeona Therapeutics Inc. - Common Stock

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).